Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Status:
Recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral
administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive
CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute